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ABSTRACT
Renal cell carcinoma is one of the most common malignancy in adults, its 
prognosis is poor in an advanced stage and early detection is difficult due to the 
lack of molecular biomarkers. The identification of novel biomarkers for RCC is an 
urgent and meaningful project. Long non-coding RNA (lncRNA) is transcribed from 
genomic regions with a minimum length of 200 bases and limited protein-coding 
potential. Recently, lncRNAs have been greatly studied in a variety of cancer types. 
They participate in a wide variety of biological processes including cancer biology. In 
this review, we provide a new insight of the profiling of lncRNAs in RCC and their roles 
in renal carcinogenesis, with an emphasize on their potential in diagnosis, prognosis 
and potential roles in RCC therapy.
INTRODUCTION
Renal cell carcinoma (RCC) is one of the most 
common urinary tract malignancies in adults. In 2016, 
62,700 newly identified cases and 14240 deaths from kidney 
and renal pelvis, cancer was estimated to occur in the United 
States [1]. With mortality at about 3% of all cases and the 
rate continues to remain very high [1]. In China, an estimated 
of 66.8 ‰ new cases and 23.4 ‰ deaths from renal cancer 
occurred in 2015 [2]. The most prevalent RCC histological 
subtype is clear cell RCC (ccRCC), which accounts for 
70% of RCC, followed by papillary RCC (pRCC) and 
chromophobe RCC (chRCC) (with a prevalence of 10 and 
5%, respectively) [3]. In 2016, world health organization 
(WHO) modified the classification of RCC and added 
several newly recognized renal tumors [4].
The tumorigenesis of RCC is extremely complex, 
not only entailing genetic changes but also including 
dysregulation of epigenetic pathways [5]. Many well-
known key signal transduction pathways such as VHL/
HIF, PI3K/Akt/mTOR, Raf/MAPK/ERK Jak/Stat, and 
Wnt-β-catenin pathway have been demonstrated to be 
involved in the pathogenesis and development of RCC 
[6–10]. Although great insight into the epigenetics of 
RCC has been made, for instance, DNA methylation [11], 
histone modification [12], as well as noncoding RNA 
[13]. But the underlying epigenetic mechanisms still 
need to be further studied. Currently, there are no specific 
and effective molecular biomarkers for RCC. Thus, the 
identification of novel biomarkers for RCC is extremely 
urgent and maybe further serve as therapeutic targets for 
the treatment.
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It is estimated that 80% of the human genome is 
transcribed. But only 1-2% of the whole genome is protein-
encoded. Remaining non-coding portions of the genome 
transcription products are non-coding RNAs, they are 
different in biogenesis, properties and functions [14, 15]. 
There are many famous non-cording RNAs, microRNAs 
(miRNAs), small interfering RNAs (siRNAs), transfer 
RNAs (tRNAs), ribosomal RNAs (rRNAs), small nuclear 
RNAs (snRNAs), small nucleolar RNAs (snoRNAs), all 
of which play critical roles in mammalian cells [16]. Most 
of them are transcribed by RNA polymerase II; some are 
transcribed by RNA polymerase III [16]. They participate 
in the epigenetic regulation of other molecules, binding to 
DNAs, proteins and/or other RNAs [17, 18]. Recently, a 
newly discovered type of long non-coding RNA molecules 
(lncRNAs), which are over 200 nucleotides have been 
greatly studied in multiple diseases and biology [19]. The 
functions and mechanisms of lncRNAs in mammalian 
cells are described in detail in Figure 1 [20–32]. Moreover, 
lncRNAs are involved in cancer biology and have been 
listed into one of the hallmarks of cancer [33, 34]. 
They are associated with oncogenesis and may serve as 
promising a new type of biomarkers for tumor diagnosis, 
prognosis, even in targeted gene therapy [19, 35, 36].
LncRNAs have been found involved in tumorigenesis, 
disease progression and metastasis of RCC. They function 
as oncogenes or tumor suppress genes and regulate multiple 
biologic or pathological processes, which are shown in 
Figure 2. But the underlying mechanisms still need to be 
further explored. In this systematic review, we focus on the 
expression profile of lncRNAs in RCC, with emphasize on 
the roles of oncogenesis, diagnosis, progression, prognosis 
and the potential of application in RCC therapy.
LNCRNAS IN RCC
Aberrant expression profiling of lncrnas in RCC
Many studies about lncRNAs expression profiling 
have been carried out in RCC. The determination of their 
interaction with other molecules and functional analysis is 
also booming in recent years. The most popular methods 
for the study of lncRNAs expression profiles of RCC are 
microarray assay and ChIP-Seq in small sample trials 
[37–43]. If certain lncRNAs are found to be obviously 
dysregulated, following qPCR experiments to demonstrate 
the significance in large scale samples are preferred, some 
of these significant dysregulated lncRNAs confirmed 
by qPCR may even serve as a diagnostic or prognostic 
biomarkers. [37–39]. A couple of recent studies found 
that hundreds of thousands of lncRNAs were aberrantly 
expressed in RCC tissue compared with adjacent non-
tumor tissue through genome wide assay [37–43]. We 
summarized these studies in Table 1 in detail [37–43]. In 
addition, lncRNAs deregulated in RCC are shown in Table 
2A and Table 2B; the functions, targeted genes/signaling, 
and the mechanisms involved are also indicated [44–67].
The lncRNAs aberrantly expressed maybe participate 
in the carcinogenesis and progression of RCC. In addition, 
lncRNA profiling and the research results indicate that 
lncRNAs may be suitable for diagnostic, even in the 
prediction of prognostic purposes for RCC. A deeper study of 
Figure 1: The functions and mechanisms of long non-coding RNAs. Accumulated evidence show that lncRNAs play important 
roles in a wide variety of biological processes, mainly in three aspects: 1. In the regulation of gene transcription, such as regulation of basal 
transcription machinery, gene-specific transcription and transcribed by RNA polymerase III; 2. In post-transcriptional regulation, such as 
splicing, translation, and siRNA-directed gene regulation; 3. In epigenetic regulation, such as imprinting, telomeric non-coding RNAs and 
Xist and X-chromosome inactivation.
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these lncRNAs may pave a way for a further understanding 
in the basic science of RCC. Despite numerous efforts 
have been made, the mechanisms of lncRNAs, such as the 
transduction pathways and regulation functions of lncRNAs 
in RCC still need to be explored in further detail.
Diagnosis and biomarkers
Many studies of determining aberrant lncRNAs 
expression for diagnostic purpose and the identification of 
novel deregulated lncRNAs as biomarkers for RCC have 
been carried out. A recent study found that the expression 
level of CYP4A22-2/3 can discriminate ccRCCs from 
normal kidney tissues [68]. In another study, lncRNA-
ATB was found to be elevated in metastatic RCC patients, 
and higher expression of lncRNA-ATB correlated with 
disease progression and a more invasive feature, as well 
as metastasis [48]. In addition, RCCRT1 has a significant 
relationship with clinicopathologic features of ccRCC 
patients, including the size of tumor, the pathological 
staging and tumor grade [49], it is also associated with 
metastasis of lymph node as well as distal metastasis 
in ccRCC [49]. Moreover, TCL6 expression was an 
independent predictor of ccRCC aggressiveness and was 
negatively correlated with the T, N, M, and TNM stage 
[65].
The technique for detection and measurement of 
specific serum lncRNAs has become feasible, which 
provides a new method without invasiveness for the 
identification of new biomarker for cancer. Recent studies 
found that serum lncRNAs are useful for the diagnosis 
of multiple types of cancer, such as bladder cancer [69], 
liver cancer [70], cervical cancer [71], gastric cancer [72], 
colorectal cancer [73, 74] and breast cancer [75] etc, these 
serum lncRNAs may even serve as prognostic biomarkers 
[69, 72, 74]. Serum lncRNAs in RCC patients are also 
Figure 2: The functions of lncRNAs in pathogenesis and potential clinical applications in RCC. LncRNAs play multiple 
functions in the context of RCC, including regulating cell proliferation, cell cycle, apoptosis, invasion, migration, and metastasis in 
the forms of oncogenes or tumor suppressor genes. Some lncRNAs maybe serve as therapeutic targets and have the potential of the 
clinical application. Red arrows indicate promoted signaling pathways. Green arrows indicate inhibited signaling pathways. LncRNAs 
in black font indicate oncogenes. LncRNAs in white font indicate tumor suppressor genes. Some lncRNAs have multiple functions (for 
example, MALAT1 promotes cell proliferation, invasion, migration, and metastasis). Abbreviations: SPRY4-IT1: SPRY4 intronic transcript 
1; HOTAIR: Hox transcript antisense intergenic RNA; UCA1: urothelial carcinoma-associated 1; lncRNA-ATB: lncRNA activated by 
TGF-β; MALAT1: metastasis-associated lung adenocarcinoma transcript 1; Linc00152: long intergenic noncoding RNA 152; TUG1: 
Taurine up-regulated gene 1; HEIRCC: high-expressed in renal cell carcinoma, lncRNA TCONS_00006756; CRNDE: colorectal neoplasia 
differentially expressed; CADM1-AS1: lncRNA cell adhesion molecule 1 antisense, lncRNA (RNA176206/ENST00000546273) located in 
the antisense direction of a coding exon of the cell adhesion molecule1 (CADM1); TRIM52-AS1: TRIM52 antisense RNA 1; GAS-5: growth 
arrest specific 5; MEG3: maternally expressed gene 3; TCL6: T-cell leukemia/lymphoma 6; CASC2: cancer susceptibility candidate 2; 
NBAT-1: neuroblastoma associated transcript 1; SRLR: sorafenib resistance-associated lncRNA in RCC; ARSR: lncRNA activated in RCC 
with sunitinib resistance, ENST00000424980.
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Table 2A: Upregulated lncRNAs in RCC
lncRNAs Specimens Functions Target genes/Signalings
Pathways/Mechanisms 
involved
Referances
SPRY4-IT1 RCC tissues, cell lines oncogene proliferation, migration, invasion 44
HOTAIR cell lines oncogene H3K27me, EZH2,  
miR-141, Ago2
proliferation, invasion, cell 
cycle 45, 46
UCA1 RCC tissues, cell lines oncogene proliferation, migration, apoptosis 47
lncRNA-ATB RCC tissues, cell lines oncogene EMT proliferation, apoptosis, migration, invasion 48
RCCRT1 RCC tissues biomarker migration, invasion 49
MALAT1 RCC tissues, cell lines oncogene Ezh2, miR-205 proliferation, migration, invasion 50, 51
Linc00152 RCC tissues, cell lines oncogene, 
biomarker
proliferation, invasion, 
apoptosis, cell cycle 52
TUG1 RCC tissues, cell lines oncogene migration, invasion, proliferation, apoptosis 53
H19 RCC tissues, cell lines biomarker proliferation, invasion, migration 54
HEIRCC RCC tissues, cell lines oncogene EMT proliferation, apoptosis, migration, invasion 55
CRNDE RCC tissues, cell lines oncogene Wnt/β-catenin signaling proliferation, growth, cell cycle 56
uc009yby.1 RCC tissues oncogene proliferation 57
FTX RCC tissues, cell lines oncogene proliferation, cell cycle, migration, invasion 58
PVT1 RCC tissues oncogene MYC promoter hypomethylation 59
Table 1: The studies about expression profiling of lncRNAs in RCC
Author Year Country RCC 
subtype
Sample
size (n)
Differentially
expressed lncRNAs
Number
upregulated
Number
downregulated
References
Yu et al 2012 China ccRCC 6 726 146 480 37
Liu et al 2016 China not mentioned 90 3862 1649 2243 38
Deng, 
Blondeau et al 2015 Germany ccRCC 15 1308 568 740 39, 40
Qin et al 2014 China ccRCC 5 897 480 417 41
Fachel et al 2013 Brazil ccRCC 11 40 14 26 42
He et al 2016 China chRCC 59 143 41 102 43
deregulated. Wu et al performed a study that demonstrated 
that five lncRNAs are significantly dysregulated in the 
serum of RCC patients-lncRNAs (LET, PVT1, PANDAR, 
PTENP1, and linc00963)- this 5 lncRNAs serum signature 
may obtain a preferable sensitivity and specificity for 
distinguishing ccRCC patients from normal individuals [76].
Prognosis
A multitude of studies have shown that aberrant 
lncRNA expressions are associated with the disease 
overall survival (OS), the 5-year survival, the disease-free 
survival (DFS), the disease grade and stage, recurrence, 
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metastasis etc. As shown in Table 3, decreased expression 
of lncRNA NONHSAT123350, CADM1-AS1, TCL6 
and lnc-ZNF180-2 is correlated with poorer prognosis 
of RCC patients [38, 60, 65, 68]. On the other hand, 
overexpression of SPRY4-IT1, RCCRT1, MALAT1, 
Linc00152 and PVT1 shows a poor prognosis, as well [44, 
49-52, 59].
The expression level of lncRNA NONHSAT123350 
was closely associated with OS and DFS in patients 
without distant metastasis; the median values of OS and 
DFS were significantly higher among patients with high 
NONHSAT123350 expression when compared to the 
patients whose expression of NONHSAT123350 were 
low [38]. In another study, Ellinger et al reported the 
expression of lnc-ZNF180-2 significantly increased in 
advanced ccRCC tissue compared with localized ccRCC 
and normal renal tissue; a shorter period of progression-
free survival (PFS), cancer-specific survival (CSS), and OS 
following nephrectomy happened in patients with lower 
levels of lnc-ZNF180-2 in the univariate Cox regression 
analysis. Thereafter, lnc-ZNF180-2 expression levels 
showed an independent predictor of progression-free 
survival (PSF), CSS, and OS in ccRCC patients within the 
multivariate Cox regression model [68]. In addition, the 
ccRCC patients had an advanced clinical stage and poorer 
prognosis when the SPRY4-IT1 expression was at high 
level. It is identified that SPRY4-IT1 is an independent 
prognostic factor in ccRCC in Cox proportional hazard 
model [44]. DRAIC is a new tumor suppressive sequence 
which locates on chromosome 15q23. DRAIC lncRNA 
was identified downregulated as prostate cancer cells 
progress from an androgen dependent to castration 
resistant state. DRAIC overexpression indicates a 
favorable prognosis in many kinds of malignancies 
including RCC [77]. Recently, a study showed that 
high Linc00152 expression was closely associated 
with advanced TNM stage in RCC patients. Moreover, 
Linc00152 is able to serve as an independent predictor 
of OS for the patients [52]. In addition, eight lncRNAs 
transcribed from the loci (ACTN4, CSNK1D, DNAJC3, 
GIGYF2, HDAC5, PTPN3, RAB25, and VPS13B) were 
detected as altered in the expression profiles in both of the 
malignancy and the survival outcomes [42]. Furthermore, 
PVT1 was strongly overexpressed in ccRCC and 
associated with the enhancement of MYC signaling and 
poorer clinical outcome [57].
Therapy
Good ways to study the potential therapeutic 
function in cancer include lncRNAs are through loss-of-
function or gain-of-function, RNA interfering technology, 
genetic loss-of-function models, or overexpression [33]. 
Therapeutic silencing or overexpression of these lncRNAs 
might be a viable therapeutic option to reduce the growth 
and/or metastatic potential of RCC. LncRNAs that may 
serve as therapeutic targets for RCC are listed in Table 4 
and discussed as below.
HOTAIR
HOTAIR is transcribed from antisense strand of 
HOXC gene cluster present in chromosome 12 with a 
Table 2B: Downregulated lncRNAs in RCC
lncRNAs Specimens Functions Target genes/Signalings
Pathways/Mechanisms 
involved
Referances
CADM1-AS1 RCC tissues tumor suppressor CADM1
cell proliferation, apoptosis 
and migration 60
TRIM52-AS1 RCC tissues tumor suppressor
proliferation, cell migration 
and apoptosis 61
GAS-5 RCC tissues tumor suppressor
proliferation, apoptosis, cell 
cycle, migration, invasion 62
MEG3
RCC tissues,cell 
lines
tumor 
suppressor
Bcl-2, rocaspase-9, leaved 
caspase-9, cytochrome c
apoptosis, mitochondrial 
pathway 63
BX357664
RCC tissues,cell 
lines
tumor 
suppressor
EMT, MMP2, MMP9, 
TGF-β1/p38/HSP27
proliferation, migration, 
invasion, cell cycle 64
TCL6 RCC tissues tumor suppressor proliferation, apoptosis 65
CASC2
RCC tissues,cell 
lines
tumor 
suppressor miR-21 proliferation, migration 66
NBAT-1
RCC tissues,cell 
lines
prognostic 
biomarker
proliferation, migration, 
invasion 67
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length of 2.2kb [78]. Recent study find that it can regulate 
EMT and is involved in Notch pathway [79]. Moreover, 
HOTAIR is a target of miR-141, inhibiting HOTAIR 
function in an Ago2-dependent manner [46]. Through 
RNAi technology, HOTAIR knockdown can affect cell 
cycle in G0/G1 phase and decrease cell proliferation and 
invasion of RCC cells [45]. The inhibiton of HOTAIR also 
suppressed tumor formation in the xenograft experiments 
in vivo [45]. Further studies are urgent for determining 
the regulatory mechanisms of HOTAIR, together with 
the interactions with epigenetic processes, such as DNA 
methylation, histone modification, microRNA and 
ubiquitin, by which new therapeutic targets might be 
developed in the treatment of RCC.
RCCRT1
RCCRT1 is upregulated in RCC compared with 
tumor adjacent tissue, particularly in high-grade RCC 
tissue. It is considered to be an oncogene of RCC, and 
elevated expression of RCCRT1 may predict dismal 
survival of RCC patients [49]. The knockdown of 
RCCRT1 by RNAi technique can suppress migration and 
invasion in RCC cell lines [49].
MALAT1
MALAT1 also called nuclear-enriched abundant 
transcript 2 (NEAT2) or Mhrt, it is one of the up-regulated 
nuclear lncRNAs in mammals [82]. The expression 
of MALAT1 is found to be upregulated in RCC tissues 
compared with corresponding normal tissues [50, 51]. 
Over-expression of MALAT1 indicates a more aggressive 
feature of the tumor and predicts a poorer OS than down-
expression of MALAT1 in patients with ccRCC [50, 51]. 
In vitro experiments found that the inhibition of MALAT1 
not only suppressed cell proliferation, promoted apoptosis, 
but also inhibited migration, and invasion of RCC cells 
[50, 51]. Thus, inhibition of MALAT1 may become a 
promising strategy for RCC therapy.
H19
The lncRNA H19 is another well-known oncogene 
in various cancer types, tumorigenesis, and cancer 
progression. It is transcribed from the sequence localized 
at 11p15.5 of the human genome. It is associate with 
disease progression and poorer prognosis of RCC 
patients [54]. Moreover, inhibition of H19 can suppress 
proliferation, invasion, and migration of RCC cells [54].
CADM1-AS1
LncRNA CADM1-AS is considered to be involved 
in the carcinogenesis of RCC. It is found to be decreased 
in RCC tissues [60]. Down-regulation of CADM1-
AS1 correlates with advanced disease staging and poor 
prognosis of patients with ccRCC [60]. Over-expression 
of CADM1-AS1 can significantly decrease cell growth 
and migration, as well as increase apoptosis in RCC cells 
[60]. Therefore, CADMA1-AS1 maybe become a suitable 
therapeutic marker for RCC.
LncRNA-SRLR and lncARSR
Targeted therapy drugs, such as sorafenib and 
sunitinib, appear to increase the survival rate of RCC 
patients. But targeted therapy resistance is a major obstacle 
for the treatment of advanced and/or metastatic RCC. 
LncRNA-SRLR (sorafenib resistance-associated lncRNA 
in RCC) was found upregulated in intrinsically sorafenib 
resistant RCCs. Interestingly, lncRNA-SRLR knockdown 
sensitized nonresponsive RCC cells to sorafenib treatment, 
whereas the overexpression of lncRNA-SRLR conferred 
sorafenib resistance to responsive RCC cells. The 
underlying mechanism is that lncRNA-SRLR directly 
binds to NF-κB and promotes IL-6 transcription, leading to 
the activation of STAT3 and the development of sorafenib 
tolerance. A STAT3 inhibitor and IL-6-receptor antagonist 
both restored the response to sorafenib treatment. 
Moreover, high levels of lncRNA-SRLR correlated with 
poor responses to sorafenib therapy in RCC patients [87]. 
Table 3: Prognostic lncRNAs in RCC
lncRNAs Prognostic information Referances
CADM1-AS1 decreased expression, poor prognosis (OS) 60
TCL6 low expression, poor prognosis (OS) 65
NONHSAT123350 low expression, poor prognosis (DFS,OS) 38
lnc-ZNF180-2 low level, poor progression-free, CSS and OS 68
SPRY4-IT1 high expression, poor prognosis (OS) 44
RCCRT1 high expression, poor survival 49
MALAT1 high expression, poor prognosis (OS) 50
Linc00152 high expression, poor prognosis (OS) 52
DRAIC overexpression, good prognosis 77
PVT1 high expression, poor prognosis (OS) 59
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Table 4: LncRNAs potentially serve as therapeutic targets for RCC
LncRNAs Location Properties/Mechanisms References
HOTAIR chromosome 12 recruit and bind on the locus of EZH2 and H3K27me3 80
inhibit cycle-related genes p53, p21 and p16 80
modulate covalent histones 80
interact with methyltransferase PRC2, histone 
demethylase LSD1
80
regulates gene silencing 80
required for H3K27 trimethylation 81
transcriptional silencing across the HOXD 
locus 81
RCCRT1 chr5:137801181-
137805004
upregulated in RCC 49
upregulated predicts poor survival of RCC 49
MALAT1 chromosome 11q13 independent predictor of OS in ccRCC 50, 51
sequester serine/arginine splicing factors in 
nuclear speckle domains
83, 84
regulate alternative splicing 84
transcriptional activation of MALAT1 by c-Fos 
contribute to oncogenesis 51
interact with Ezh2 51
reciprocally repressed with miR205 51
regulate EMT via E-cadherin and β-catenin 51
promote ZEB2 expression by sponging miR-
200s 85
H19 11p15.5 exon 1 of H19 harbors a miRNA-containing hairpin 86
serve as the template of two miR6755p and 
miR6753p 86
LncRNA-SRLR 3q24
upregulated in intrinsically sorafenib resistant 
RCC 87
LncARSR
9q82.120.717-
82.185.824
promote sunitinib resistance of RCC 88
competitively bind to miR-34/miR-449 88
facilitate AXL and c-MET expression 88
exosome-transferred lncARSR confer sunitinib 
resistance 88
targeting lncARSR restores sunitinib response 
in RCC 88
CADM1-AS1
antisense direction of a 
coding exon of
the cell adhesion 
molecule 1 (CADM1)
involved in renal carcinogenesis
independent prognostic factor for ccRCC
60
60
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LncARSR (activated in RCC with sunitinib resistance, 
ENST00000424980) was a newly identified lncRNA to 
promote the sunitinib resistance of RCC. It is upregulated 
in sunitinib resistant RCC. By targeting lncARSR and the 
underlining pathways involved, sunitinib resistance RCC 
can restore the sensitivity to sunitinib [88]. Another study 
showed that lncARSR was upregulated in primary renal 
cancer stem cells (CSCs) and was associated with a poor 
prognosis of ccRCC. Knockdown of lncARSR attenuated 
the self-renewal, tumorigenicity, and metastasis of renal 
CSCs. Conversely, forced lncARSR expression enhanced 
CSC properties of RCC cells. The mechanism showed 
that the binding of lncARSR to Yes-associated protein 
(YAP) impedes LATS1-induced YAP phosphorylation and 
facilitates YAP nuclear translocation [89].
These findings are extremely meaningful, because 
lncRNAs may act as predictors and potential promising 
therapeutic targets for target therapy resistance, and 
may further improve the management of RCC patients 
receiving target therapy. If these lncRNAs could be applied 
to the treatment of RCC, it would benefit the patients, not 
only on efficacy, but also economically. Hence, further 
studies should be made for the identification of lncRNAs 
as targeted therapy biomarkers and application for RCC 
treatment strategy.
Specific molecular mechanism of lncrnas in RCC
Hypoxia-inducible factor-2α (HIF2A) signaling 
participates in the RCC oncogenesis and progression 
as reported [90]. In this pathway, LncRNA-suppressing 
androgen receptor in renal cell carcinoma (SARCC) 
serves as a critical regulator, it connects with the AR/
HIF2A/MYC axis to regulate cell growth in response 
to hypoxia. LncRNA-SARCC suppresses hypoxic 
cell cycle progression in VHL mutant type of RCC 
cells and de-represses it in VHL restored type of RCC 
cells. Mechanistically, lncRNA-SARCC binds to and 
deactivates androgen receptor (AR) protein to modulate 
AR post transcription thus block the AR/HIF2A/ MYC 
signals; on the other hand, HIF2A is able to regulate the 
lncRNA-SARCC expression on the transcription level by 
binding to hypoxia responsive elements on the lncRNA-
SARCC promoter vice versa [90]. There is a negative 
feedback regulation loop between complex of LncRNA-
SARCC/AR and HIF2A pathway, by which may result a 
differentially regulated RCC disease progression in a VHL 
dependent way [90]. Thereafter, future studies should be 
done to identify the association of lncRNAs and HIF 
signals in RCC.
Interestingly, a recent study from China 
established a novel method designed to identify lncRNA 
competitively regulated signal subpathways, so called 
subpathway-LNCE, which can identify lncRNA 
competitively regulated functions. The functional roles 
of these competitive regulation lncRNAs have not be 
well characterized in diseases. Moreover, the method 
integrated lncRNA-mRNA expression profile and pathway 
topologies [91].
CONCLUSIONS
In conclusion, lncRNAs are aberrantly expressed 
in RCC, and participate in important roles in the 
regulation of RCC. They have a significant impact on 
our understanding the mechanisms of pathogenesis, 
progression and metastasis of RCC. They are also involve 
in key pathological process in RCC, the cell proliferation, 
cell cycle control, apoptosis, local invasion and distal 
metastasis. To deeply identify the mechanisms regarding 
how specific lncRNAs affect RCC and the regulatory 
mechanisms, further exploration and continued studies 
are required. At the same time, the lncRNA transduction 
pathway in RCC still needs to be further explored. 
Moreover, lncRNAs may act as promising new biomarkers 
for RCC, with the capability of improving diagnosis, 
predicting prognosis, and even in the improvement of 
therapeutic strategy for RCC patients. Several newly 
identified lncRNAs have the function of predicting 
target therapy resistance, by targeting these lncRNAs, 
the resistance of target therapies may be restored their 
sensitivity. RCC is an immunotherapy effective disease 
and the determination of whether lncRNAs could regulate 
the immune pathways of RCC such as PD-1 or PD-L1 
signaling are expected. In any cases, to deeply understand 
the mechanisms of lncRNAs in RCC can not only help to 
uncover the tumorigenesis, but also have the possibility of 
application in the clinical management.
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